1] Center of Experimental Medicine, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany [2] Institute of Molecular Oncology, University Medical Center Göttingen, Göttingen, Germany.
1] Institute of Pathology Nordhessen, Kassel, Germany [2] Center for Pathology and Forensic Medicine, Department of Pathology, University Medical Center Göttingen, Göttingen, Germany.
Oncogene. 2015 Jan 22;34(4):465-73. doi: 10.1038/onc.2013.558. Epub 2014 Jan 20.
The estrogen receptor alpha (ERα) is the central transcriptional regulator of ductal mammary epithelial lineage specification and is an important prognostic marker in human breast cancer. Although antiestrogen therapies are initially highly effective at treating ERα-positive tumors, a large number of tumors progress to a refractory, more poorly differentiated phenotype accompanied by reduced survival. A better understanding of the molecular mechanisms involved in the progression from estrogen-dependent to hormone-resistant breast cancer may uncover new targets for treatment and the discovery of new predictive markers. Recent studies have uncovered an important role for transcriptional elongation and chromatin modifications in controlling ERα activity and estrogen responsiveness. The human Suppressor of Ty Homologue-6 (SUPT6H) is a histone chaperone that links transcriptional elongation to changes in chromatin structure. We show that SUPT6H is required for estrogen-regulated transcription and the maintenance of chromatin structure in breast cancer cells, possibly in part through interaction with RNF40 and regulation of histone H2B monoubiquitination (H2Bub1). Moreover, we demonstrate that SUPT6H protein levels decrease with malignancy in breast cancer. Consistently, SUPT6H, similar to H2Bub1, is required for cellular differentiation and suppression of the repressive histone mark H3K27me3 on lineage-specific genes. Together, these data identify SUPT6H as a new epigenetic regulator of ERα activity and cellular differentiation.
雌激素受体 α(ERα)是导管型乳腺上皮谱系特化的核心转录调节剂,是人类乳腺癌的重要预后标志物。尽管抗雌激素疗法最初在治疗 ERα 阳性肿瘤方面非常有效,但大量肿瘤会进展为耐药性、分化程度更低的表型,并伴有存活率降低。更好地了解从雌激素依赖性到激素抵抗性乳腺癌进展的分子机制,可能会发现新的治疗靶点和新的预测标志物。最近的研究揭示了转录延伸和染色质修饰在控制 ERα 活性和雌激素反应性方面的重要作用。人类同源物 6(SUPT6H)是一种组蛋白伴侣,它将转录延伸与染色质结构的变化联系起来。我们表明,SUPT6H 是雌激素调节转录所必需的,并且在乳腺癌细胞中维持染色质结构,这可能部分是通过与 RNF40 相互作用和调节组蛋白 H2B 单泛素化(H2Bub1)来实现的。此外,我们证明 SUPT6H 蛋白水平随乳腺癌恶性程度的增加而降低。一致地,SUPT6H 与 H2Bub1 相似,是细胞分化所必需的,并抑制特定于谱系的基因上的抑制性组蛋白标记 H3K27me3。总之,这些数据将 SUPT6H 确定为 ERα 活性和细胞分化的新表观遗传调节剂。